WTF !!!, page-41

As long as you and others can understand it, that is also very beneficial.

One thing I should have added, as per mentioned by Dr Claasen on the latest results of the 202 study was:

“I am gratified to see that the work we have done over the last several years is bearing fruit as we enhance our understanding of MSA. This has led to improved patient selection and optimized biomarker endpoints in the Alterity Phase 2 trials. The clinical observations in the ATH434-202 study are supported by the objective biomarkers of brain volume, brain iron, and NfL. These early data increase our confidence that we have chosen the right biomarker and clinical endpoints to evaluate the potential effect of ATH434 in individuals with MSA'.

Therefore to me also proves, as mentioned after the result of this report, is that they have seen changes in brain mass volume. Hence why they are discussing to add brain volume measurement as a FDA requirement measurement. Hopefully theyll just add it as a look at this also FDA.